The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …
Read More »GLP-1s and Reproductive Health: What to Know About Fertility, Pregnancy, and PCOS
GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …
Read More »Off-Ramp Planning for GLP-1s: When and How to Taper Without Losing Progress
As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …
Read More »GLP-1s and Food Noise: Helping Patients Understand Hunger, Cravings, and Control
Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …
Read More »GLP-1s in Young Adults: Rethinking Metabolic Risk and Early Intervention
For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …
Read More »Stopping and Restarting GLP-1s: What Happens When Access Is Interrupted?
What happens when a medication that quietly supports weight loss and glucose control suddenly disappears? For many patients, an unexpected break in GLP-1 therapy feels like pulling the rug out from under hard-earned progress. Supply shortages, insurance denials, side effects, or planned drug holidays are now common reasons people stop …
Read More »Talking About Off‑Label GLP‑1 Use: How to Answer Patients Without Overpromising
A patient walks into your exam room, hopeful after reading that a diabetes drug might help with memory loss, addiction, or even anxiety. You know they’re talking about GLP‑1s—but how do you respond when the science is still unfolding? As GLP‑1 receptor agonists capture public attention for much more than …
Read More »GLP‑1 Stewardship in the Clinic: Prioritizing, Deprescribing, and Switching Without Chaos
What happens when a breakthrough therapy becomes too popular for its own good? Clinics across the country are struggling to manage demand for GLP‑1 receptor agonists amid soaring prescriptions, medication shortages, and shifting insurance coverage. Without a strategy, patients fall through the cracks—and providers are left making chaotic case-by-case decisions. …
Read More »GLP‑1s on the WHO Radar: Turning Global Guidance Into Everyday Prescribing
What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …
Read More »Aiming for MASH Resolution: How to Use GLP‑1s in Liver‑First Diabetes Care
What if the key to resolving both diabetes and liver disease lies in a single therapeutic approach? As rates of metabolic dysfunction-associated steatohepatitis (MASH) rise among people with type 2 diabetes, many clinicians are rethinking how they prioritize treatment. Rather than treating glucose and liver health in silos, combining therapies …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.